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Abstract
Background: We previously showed that the probiotic mixture, VSL#3, prevents the onset of ileitis in SAMP/YitFc (SAMP)
mice, and this effect was associated with stimulation of epithelial-derived TNF. The aim of this study was to determine the
mechanism(s) of VSL#3-mediated protection on epithelial barrier function and to further investigate the ‘‘paradoxical’’
effects of TNF in preventing SAMP ileitis.
Methods: Permeability was evaluated in SAMP mice prior to the onset of inflammation and during established disease by
measuring transepithelial electrical resistance (TEER) on ex vivo-cultured ilea following exposure to VSL#3 conditioned
media (CM), TNF or VSL#3-CM + anti-TNF. Tight junction (TJ) proteins were assessed by qRT-PCR, Western blot, and
confocal microscopy, and TNFRI/TNFRII expression measured in freshly isolated intestinal epithelial cells (IEC) from SAMP
and control AKR mice.
Results: Culture with either VSL#3-CM or TNF resulted in decreased ileal paracellular permeability in pre-inflamed SAMP,
but not SAMP with established disease, while addition of anti-TNF abrogated these effects. Modulation of the TJ proteins,
claudin-2 and occludin, occurred with a significant decrease in claudin-2 and increase in occludin following stimulation with
VSL#3-CM or TNF. TNF protein levels increased in supernatants of SAMP ilea incubated with VSL#3-CM compared to
vehicle, while IEC-derived TNFR mRNA expression decreased in young, and was elevated in inflamed, SAMP versus AKR
mice.
Conclusions: Our data demonstrate that the previously established efficacy of VSL#3 in preventing SAMP ileitis is due to
direct innate and homeostatic effects of TNF on the gut epithelium, modulation of the TJ proteins, claudin-2 and occludin,
and overall improvement of intestinal permeability.
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Introduction
Inflammatory bowel disease (IBD) is a chronic relapsing
inflammatory disorder of the gastrointestinal tract that includes
Crohn’s disease (CD) and ulcerative colitis (UC). Although the
precise etiology is currently unknown, it is generally accepted that
IBD results from dysregulated immune responses to environmental
factors in genetically susceptible individuals. As early as 1972,
Shorter et al. proposed the hypothesis that the primary defect in
CD may be due to an abnormal gut epithelial barrier, and further
stipulated that compromised barrier function allows for increased
passage of antigen(s) across the intestinal mucosa, resulting in an
overactive immune response and chronic inflammation [1].
Further support of this concept comes from studies demonstrating
that IBD patients display: 1) increased intestinal epithelial
permeability versus control subjects, 2) disrupted barrier function
that is not isolated to sites of active inflammation, and 3) first-
degree relatives, as well as CD patients prior to disease relapse,
possess increased gut permeability [2–6]. Together, these data
suggest that patients with IBD have abnormally high gastrointes-
tinal epithelial permeability and barrier dysfunction that may be
a predisposing factor to chronic intestinal inflammation.
Similarly, SAMP1/YitFc (SAMP) mice display an inherent
increase in small intestinal epithelial paracellular permeability that
precedes the histologic onset of ileitis and is independent of
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commensal flora colonization [7,8]. The SAMP strain represents
a spontaneous model of chronic intestinal inflammation that
resembles CD for disease location (i.e., terminal ileum), histologic
features, and response to standard therapies used to treat Crohn’s
patients [9–12]. Altered barrier function in the SAMP small
intestine may stem from aberrant expression of claudin-2 and
occludin that were found to be increased and decreased,
respectively, compared to the control parental (AKR) strain [8].
In fact, increased claudin-2 and decreased occludin expression in
epithelial tight junction (TJ) fibrils have been shown to generate
weaker anastomoses between neighboring cells, resulting in barrier
dysfunction [13–16]. These aforementioned trends in claudin-2
and occludin expression have also been reported in patients with
both CD and UC [17,18].
Recently, our group reported that administration of the
probiotic formulation, VSL#3, prevents the onset of ileitis in
SAMP mice [19]. VSL#3 is a mixture of Streptococcus thermophilus,
three strains of Bifidobacterium and four strains of Lactobacillus, and
has been proven to be efficacious in treating established colitis in
IL-10 knockout (KO) mice [20–22], and to induce remission in
patients with UC [23–27]. In SAMP mice, the beneficial effects of
VSL#3 appear to be associated with increased production of
epithelial-derived TNF and improved barrier function [19].
However, the mechanism(s) of VSL#3 modulation of intestinal
permeability and the precise role of TNF in this process are not
fully elucidated. The goal of the present study was to determine
how VSL#3 functions to promote gut health through stimulation
of epithelial innate immunity, and to define the direct role of early
TNF expression in preventing SAMP ileitis.
We provide evidence, herein that recombinant TNF or
VSL#3-stimulated TNF, specifically improves transepithelial
permeability during the early phases of gut inflammation in
young, pre-inflamed SAMP mice, by directly regulating the TJ
proteins, claudin-2 and occludin and inducing innate, proinflam-
matory cytokine production. In addition, VSL#3-mediated
changes in epithelial permeability appear to be dependent on
decreased expression of TNFRs prior to the onset of ileitis. Our
findings provide evidence that the beneficial effect of VSL#3 on
intestinal permeability are directly mediated by a mechanism
involving modulation of TJ proteins and TNF expression in the
gut epithelium. Furthermore, our studies support the concept that
TNF, in addition to its known proinflammatory activities, may also
possess anti-inflammatory and homeostatic properties, particularly
during the earlier phases of disease.
Results
VSL#3-CM and TNF Improve Inherent Epithelial
Permeability Defect in Young SAMP Mice
The effect of VSL#3-CM and TNF in regulating small
intestinal barrier function was initially investigated by measuring
ex vivo epithelial paracellular permeability in ilea from young
SAMP mice, prior to the onset of inflammation (4-wk-old), SAMP
with established disease (.20 weeks of age), and age-matched
AKR controls (Fig. 1A and B, respectively) following treatment with
either VSL#3-CM, TNF or vehicle control. Specifically, the
change in TEER (DTEER) was measured in ilea after 1h exposure
to VSL#3-CM or TNF versus vehicle control. Baseline levels
(vehicle-treated) of 4- and .20-wk-old AKR ilea showed a de-
crease in epithelial paracellular permeability (increased TEER)
during the incubation period due to tissue ‘‘normalization’’ under
static conditions. In contrast, both 4- and .20-wk-old SAMP ilea
showed an increased in epithelial paracellular permeability
(decreased TEER), confirming the inherent defect in barrier
function in SAMP mice previously reported by our group [7].
Importantly, exposure to either VSL#3-CM or TNF improved
barrier function, and showed a decrease in ileal epithelial
paracellular permeability (increased TEER) in young (p,0.05),
but not old, SAMP mice (Fig. 1A-B). No significant differences
were observed in the DTEER from AKR ilea, regardless of age,
when exposed to either VSL#3-CM or TNF. In addition, to
determine whether the effect of VSL#3-CM on improving
epithelial barrier function in young SAMP mice may be directly
mediated by TNF, DTEER was measured on 4-wk-old SAMP ilea
cultured with VSL#3-CM in which a neutralizing antibody for
TNF was added (Fig. 1C). In fact, anti-TNF had the ability to
abrogate the effects of VSL#3-CM on epithelial paracellular
permeability and markedly decreased DTEER compared to
SAMP ilea exposed to VSL#3-CM alone (p,0.05). Taken
together, these data indicate that both VSL#3-CM and TNF
are efficacious in improving barrier function by decreasing
epithelial paracellular permeability specifically in young SAMP
that do not yet show overt histologic signs of ileal inflammation. In
contrast, these effects are not observed in older SAMP mice with
established disease or AKR controls, regardless of age. These
observations are consistent with the in vivo setting wherein orally-
administered VSL#3 to young non-inflamed SAMP, but not to
older SAMP, effectively decreases epithelial permeability and
prevents the onset of ileitis [19]. Our data further suggests that the
effects of VSL#3 on epithelial barrier function may be directly
mediated by TNF.
VSL#3-CM Stimulates Production of Innate Mucosal
Cytokines
Emerging evidence suggests that defects in innate immunity and
the inability of the gut mucosa to mount appropriate innate
immune responses may result in the initiation and perpetuation of
chronic intestinal inflammation, such as that observed in IBD
[28,29]. As such, we next tested whether probiotics are capable to
enhance, and potentially ‘‘boost,’’ gut mucosal immunity through
the production of innate-type cytokines in ileitis-prone SAMP
mice. Full-thickness ilea from pre-inflamed, 4-wk-old SAMP and
age-matched control AKR were cultured in the presence or
absence of VSL#3 and cytokine production subsequently
measured (Fig. 2). In support of our previous in vivo studies [19],
secreted TNF protein levels increased after exposure to VLS#3-
CM compared to vehicle control in SAMP mice (p,0.05).
Moreover, other early, innate cytokines also showed a trend
towards increased secretion following treatment with VSL#3-CM,
including IL-1b and IL-6, with baseline levels of these cytokines
greater than age-matched AKRs. Conversely, VSL#3-CM did
not alter production of TNF or other innate-type cytokines from
control AKR ilea. Interestingly, baseline IL-10 levels were
markedly increased in AKR ilea compared to SAMP (p,0.01),
but while VSL#3-CM had the ability to further induce IL-10
production from SAMP ilea (p,0.05), it did not modulate IL-10 in
ilea from AKR mice. The effect of VSL#3-CM on inducing TNF
secretion confirms TNF’s central role in VSL#3-mediated events,
while the induction of other innate-type cytokines suggests that
VSL#3 may play a role in augmenting global innate mucosal
immune responses, including improving epithelial barrier func-
tion.
VSL#3-CM and TNF Modulate TJ Protein Expression in
Pre-inflamed, Young SAMP Mice
To elucidate potential mechanisms involved in VSL#3- and
TNF-mediated improvement in epithelial barrier function and
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subsequent prevention of chronic intestinal inflammation in
SAMP mice [19], we first studied TJ protein mRNA expression
in full-thickness ilea from pre-inflamed SAMP following ex vivo
organ culture with either VSL#3-CM or TNF (Fig. 3). Expression
of claudins-1 and -4, and ZO-1 was not different following
exposure to either VSL#3-CM or TNF compared to vehicle
controls, while claudin-3 was significantly decreased after stimu-
lation with TNF only (p,0.05). Interestingly, treatment with either
VSL#3-CM or TNF, compared to vehicle, decreased claudin-2
and increased occludin mRNA levels (both p,0.05) in ilea from
pre-inflamed SAMP mice. VSL#3- and TNF-specific modulation
of claudin-2 and occludin in young, ileitis-prone SAMP mice was
further confirmed by in vivo experiments on isolated ileal loops in
which either VSL#3-CM or TNF was injected, followed by
epithelial immunolocalization of the aforementioned TJ proteins
(Fig. 4). Claudin-2 expression decreased, particularly in the distal
tips of ilea following treatment with VSL3#-CM, and more
prominently after TNF treatment (upper panels). Increased
claudin-2 expression was also noted in the ileal crypt regions of
VSL#3-treated SAMP, which recapitulates the characteristic
distribution of claudin-2 in the normal, uninflamed gut [8].
Occludin expression likewise increased along the crypt-villous axis
in SAMP ilea following treatment with either VSL3#-CM or
TNF, most prevalently in the distal villous tips. We next examined
the protein levels of occludin and claudin-2 in freshly IEC isolated
from SAMP mice treated with VSL#3 by Western blot.
Consistent with the aforementioned observations, occludin protein
levels were increased, while claudin-2 protein levels were markedly
decreased, compared to control mice (Fig. 4B). In order to relate
occludin and claudin-2 changes to the observed effects on
intestinal permeability, we then investigated protein expression
of the two TJ proteins in the membrane and cytosolic fractions of
isolated IEC preparations from SAMP intestinal loops treated with
either VSL#3, TNF or vehicle. Interestingly, we observed
modulation of occludin following either VSL#3 or TNF
compared to vehicle control within the membrane fraction, while
claudin-2 was increased in the cytosol, but not in the membrane
fraction (Fig. 4C). These data suggest that occludin may play
a more prominent role in modulating epithelial barrier function in
SAMP mice following VSL#3 treatment.
TNFR Expression is Essential and Contributes to the
Effects of VSL#3-CM and TNF on Regulating Intestinal
Barrier Function
We next investigated the expression of epithelial TNFRs in pre-
inflamed and inflamed SAMP ilea, and their potential contribu-
tion to the VSL#3- and TNF-mediated effects on epithelial
barrier function. TNFRI and TNFRII mRNA transcript levels
were evaluated in freshly isolated IECs from 4-wk-old (pre-
inflamed) or .20-wk-old (inflamed) SAMP mice (Fig. 5A).
Although neither TNFRI nor TNFRII mRNA transcript levels
changed in IEC from AKR prior to the onset of inflammation to
established inflammation, mRNA expression of both TNFRs was
strikingly increased in IEC from pre-inflamed compared to
inflamed SAMP mice (both p,0.01). Interestingly, IEC derived
from young, pre-inflamed SAMP displayed decreased mRNA
transcripts for TNFRI and TNFRII compared to age-matched
AKR (both p,0.05), while during established disease, mRNA
expression for both TNFRs was markedly increased in SAMP IEC
versus control AKR (both p,0.05) (Fig. 5A).
Figure 1. VSL#3 decreases epithelial paracellular permeability
in a TNF-dependent manner on ilea from pre-inflamed SAMP
mice. Epithelial paracellular permeability was assessed by measuring
TEER on ex vivo cultured full-thickness ilea from (A), 3- to 4-wk old
SAMP, prior to the onset of inflammation, (B), older (.20 wks) SAMP
with established ileitis, and age-matched AKR controls at T0 and after
1 h (DTEER) exposure to VSL#3-CM or TNF (N= 6/exp grp). **p,0.01 vs.
age- and treatment-matched AKR, *p,0.05 vs. vehicle cont. (C),
Addition of a neutralizing antibody against TNF abrogated the positive
effects of VSL#3 on DTEER in pre-inflamed ilea from young SAMP (N=7
exp grp). *p,0.05 vs. vehicle cont. Results are combined from two
independent experiments and expressed as mean 6 SEM.
doi:10.1371/journal.pone.0042067.g001
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Finally, we explored the effects of VSL#3-CM and TNF on
epithelial paracellular permeability in mice deficient in both
TNFRI and TNFRII (TNFR KO mice). DTEER was measured in
ilea after 1 h exposure to VSL#3-CM or TNF (10 ng/ml) versus
vehicle control. No differences were observed in DTEER from
TNFR KO ilea when exposed to either VSL#3-CM or TNF. In
contrast, stimulation with either VSL#3-CM or TNF markedly
improved (increased TEER) epithelial barrier function of WT
control mice (p,0.05). Together, this data suggest that TNFRs are
essential in mediating VSL#3- and TNF-dependent changes in
intestinal epithelial paracellular permeability, and that TNFR
expression on IEC may contribute to the overall effects of VSL#3
on mucosal barrier function.
Materials and Methods
Mice
SAMP mice were originally propagated at the University of
Virginia and then at Case Western Reserve University (CWRU),
with founders provided by S. Matsumoto (Yakult Central Institute
for Microbiological Research, Tokyo, Japan) [9,10]. AKR/J, as
well as mice deficient in both TNFRII and II, i.e., B6; 29S-
Tnfrsf1atm1ImxTnfr1btmImx/J (TNFR KO) and WT controls
were purchased from The Jackson Laboratory (Bar Harbor, ME).
All experimental mice were maintained under SPF conditions, fed
standard laboratory chow (Harlan Teklad, Indianapolis, IN), and
kept on 12 h light/dark cycles. All procedures were approved by
the CWRU’s Institutional Animal Care and Use Committee
(IACUC) (animal protocols 2009-0186 and 2011-0196) and were
in accordance with the Association for Assessment and Accred-
itation of Laboratory Animal Care (AAALAC) guidelines.
Ex vivo Permeability and Organ Culture Assays
VSL#3 (provided by Dr. Claudio De Simone, VSL#3
Pharmaceuticals, Rome, Italy) conditioned media (VSL#3-CM)
was prepared as previously described [30], and diluted 1:10 in
unconditioned media for ex vivo permeability and organ culture
assays. Transepithelial electrical resistance (TEER) assays were
performed according to a previously described method [31]. In
brief, distal ilea from experimental mice were removed, flushed
with 0.9% NaCl, and opened longitudinally to expose mucosal
surfaces. Two 3-mm squares of tissue were excised and placed
apical side up on separate precut and wetted 0.4-mm pore size
membranes (Costar Incorporated, Corning, NY). Specimens were
mounted between two custom made Plexiglass discs with laser cut
holes (2-mm diameter) to expose apical and basolateral tissue
surfaces, placed into Snapwell inserts (Costar) apical side up, and
fitted into a 6-well plate. 2 ml of RPMI only (control), VSL#3-
CM, RPMI + TNF (10 ng/ml; Peprotech, Rocky Hill, NJ), or
Figure 2. Increased ileal innate-type cytokine secretion following VSL3# treatment. Supernatants were collected from cultured ilea that
were exposed apically to VSL#3-CM and cytokine protein levels measured as described in Methods and Materials. *p,0.05 and **p,0.01 vs. vehicle
control or age- and treatment-matched AKR. Results are representative of two independent experiments (N = 6/exp grp) and expressed as mean 6
SEM.
doi:10.1371/journal.pone.0042067.g002
Figure 3. VSL#3 and TNF modulate TJ protein expression in
ilea from pre-inflamed SAMP mice. mRNA transcript levels of TJ
proteins (claudins 1–4, ZO-1, and occludin) were measured by qRT-PCR
and expressed relative to ß-actin in full-thickness ilea from experimental
mice following ex vivo culture with either VSL#3-CM or TNF. The
greatest differences in expression were seen in claudin-2 (decrease) and
occludin (increase) after either VSL#3-CM or TNF stimulation, and in
claudin-3 (decrease) after TNF stimulation only. No differences in
expression were noted for claudins 1, 4, and ZO-1 following exposure to
either VSL#3-CM or TNF. *p,0.05 vs. vehicle cont. Results are
representative of two independent experiments (N= 6/exp group)
and expressed as mean 6 SEM.
doi:10.1371/journal.pone.0042067.g003
TNF-Mediated Intestinal Permeability by Probiotics
PLoS ONE | www.plosone.org 4 July 2012 | Volume 7 | Issue 7 | e42067
VSL#3-CM + a neutralizing antibody against TNF (1 mg/ml;
R&D Systems, Inc., Minneapolis, MN) was added basally or
500 ml apically. TEER readings were taken using an EVOM
voltmeter with an EndOhm chamber attachment (World Precision
Instruments, Sarasota, FL) immediately after assembling transwell
apparati and after 1 h incubation at 37uC. Baseline resistance
readings were determined in transwells containing membrane
inserts only and subtracted from sample values. In addition,
supernatants were collected from cultured ilea exposed apically to
VSL#3-CM (diluted 1:10) and secreted cytokines measured by
sandwich ELISA (eBioscience, San Diego, CA) for TNF, and by
Quansys multiplex ELISA array (Quansys, Logan, UT) for IL-1b,
IL-6 and IL-10. All ELISAs were performed according to
manufacturers’ instructions.
VSL#3 Administration Protocol
SAMP mice were administered high-dose VSL#3 (506109
CFU/day) mixed in their normal chow, as previously described
[19]. Age-matched control mice were fed unsupplemented chow.
VSL#3 was administered for 6 weeks, after which mice were
Figure 4. Localization and protein expression of epithelial claudin-2 and occludin following in vivo treatment with VSL#3-CM and
TNF. (A), Representative confocal images (40X magnification) of ileal loops from young SAMP exposed to either VSL#3-CM, TNF or vehicle control,
and immunofluorescent staining performed to detect occludin (upper panels) claudin-2 (lower panels). Epithelial occludin expression potently
increased also in the villous tips after either VSL#3-CM or TNF stimulation in SAMP ilea. Claudin-2 primarily localized to the villous tips of SAMP ilea
and decreased following VSL#3-CM, and particularly TNF, treatment. Results are representative of two independent experiments. (B), Representative
Western blot of unfractionated IEC extracts isolated from SAMP mice treated with high dose VSL#3 showing increased expression of occludin and
decreased claudin-2 protein levels compared to control. Results are representative of three independent experiments. (C), Representative Western
blots demonstrating increased protein levels of occludin in membrane vs. cytosolic fractions of IEC from SAMP ileal loops treated with either VSL#3
or TNF compared to control. Claudin-2 protein was predominantly expressed in cytosolic vs. membrane fractions, and decreased following treatment
with both VSL#3-CM and TNF compared to control. Results are representative of two independent experiments, pooling IEC from N=3 mice/exp
grp.
doi:10.1371/journal.pone.0042067.g004
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killed and ilea was collected to isolate epithelial cells as described
below.
Intestinal Epithelial Cells (IEC) Isolation
Freshly isolated IECs were harvested from ileal segments of
experimental mice as previously described [32], and processed for
quantitative real-time PCR (qRT-PCR) or Western blot analysis as
described below.
Quantitative RT-PCR
Total RNA was isolated from homogenized tissues or from
primary isolated IEC (RNeasy Mini or Miniprep Kits; Qiagen,
Valencia, CA), and subsequently converted into cDNA (Tetro
cDNA Synthesis Kit; Bioline, Taunton, MA). cDNA was
quantified using the Applied Biosystem RT-PCR detection system
and software (Applied Biosystem StepOne and StepOnePlus
system, Carlsbad, CA). qRT-PCR was performed using the
following primers: occludin (59-CCCTGACCACTATGAAA-
CAG-39 and 59-TTGATCTGAAGTGATAGGTG-39), claudin-




GATGA-39 and 59-CAGCCTGTCTGTCCTCTTCC-39), clau-
din-4 (59-AGCAAACGTCCACTGTCCTT-39 and 59-
CCCTCATCAGTCACTCAGCA), zonula occludens-1 (ZO-1)
(59-CCTAAGACCTGTAACCATCT-39 and 59-CTGATAGA-
TATCTGGCTCCT-39), and the RT2 Primer Assay used for
TNFRI and TNFRII evaluation (SABioscience, Frederick, MD).
Target mRNA was normalized to b-actin for each sample, and all
samples were run in duplicate.
In vivo Exposure of VSL#3 or TNF to Gut Mucosa using
Ileal Loop Procedure
SAMP mice were fasted 4h prior to anesthesia via nose cone
exposure to isofluorane (Baxter, Deerfield, IL) as previously
described [33]. Abdomens of experimental mice were shaved
and midline and subcostal incisions made through the dermis and
the peritoneum. A section of ileum was isolated 0.5 cm from the
cecum, a 2-cm intestinal loop fashioned, and either 100 ml of
vehicle control, VSL#3-CM or TNF (10 ng/ml) was injected into
the ileal loop. The peritoneum and dermis were then sutured and
the animal maintained under anesthesia on a 37uC heating stage.
Experimental animals were sacrificed after 2 h and ileal loops
explanted and fixed as described below or used to freshly isolate
IECs.
Immunofluorescent Detection of Claudin-2 and Occludin
Paracecal regions of the intestinal ileum were explanted and
fixed with 4% paraformaldehyde/PBS for 12 h followed by
dehydration in 30% sucrose/PBS prior to embedding in OCT
freezing media (Tissue-Tek, Sakura, Japan). 10 mm tissue sections
were cut on a CM3050s cryostat (Leica, Buffalo Grove, IL) and
mounted on Superfrost Plus slides (VWR, Batavia, IL). Tissue
sections were permeabilized and blocked in PBS containing 0.3%
Triton X-100 (Sigma-Aldrich, Milwaukee, WI) and 10% goat
serum (Jackson Immunoresearch, West Grove, PA), followed by
staining with primary antibodies for claudin-2 (1:300) or occludin
(1:100), and an Alexa Fluor-conjugated secondary antibody
(1:500). TJ proteins were then detected and immunolocalized
using Prolong Gold or Prolong Gold plus DAPI (all from
Invitrogen, Carlsbad, CA). 3D image stacks were acquired by
confocal microscopy (ZEISS LSM 510, Thornwood, NY), and
images displayed as 2D maximum intensity projections.
Subcellular IEC Fractionation
Freshly isolated IECs were harvested from ileal segments of
experimental mice in 10 mM HEPES, pH 7.4, 100 mM KCl,
3mM NaCl, 1 mM Na2ATP, 3.5 MgCl2, 1 mM PMSF, Protease
Inhibitor Cocktail and Phosphatase Inhibitor Cocktail (Sigma-
Aldrich, Milwaukee, WI). Cell lysis was achieved using cell
douncers (Fischer Scientific, Pittsburgh, PA), and lysates were
cleared of nuclear material by 1000 x g centrifugation for 10 min
at 4uC. Supernatants were then centrifuged (100,000 x g) for 1 h at
4uC to separate membrane from cytosolic fractions. Resulting
supernatants were collected as cytosolic fractions and pellets
(membrane fractions) were resuspended in RIPA buffer (Fischer
Scientific, Pittsburgh, PA) with 1% OG (n-Octyl-b-D-Glucopyr-
anoside) and then sonicated 3x (70% duty cycle) on ice.
Figure 5. SAMP ilea differentially express TNFRs, which are
essential to the effects of VSL#3-CM and TNF. (A), TNFRI and II
mRNA expression measured by qRT-PCR was decreased in freshly
isolated IEC from 4-wk-old SAMP prior to the onset of inflammation, but
increased in .20-wk-old SAMP with established disease compared to
age-matched AKR control mice (N= 6/exp grp). *p,0.05 and **p,0.01.
(B), Epithelial paracellular permeability was assessed by measuring
DTEER on ex vivo cultured full-thickness ilea from mice deficient in both
TNFRI and TNFRII (TNFR KO) and WT controls after 1 h exposure to
VSL#3-CM or TNF (N= 6/exp grp). *p,0.05 vs. WT vehicle cont.
doi:10.1371/journal.pone.0042067.g005
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Western Blot Analysis
Western blot analysis was performed on total protein extracts or
cellular fractions of freshly isolated IECs from experimental mice.
Equal amounts of protein were separated by SDS-PAGE and
transferred onto polyvinylidene fluoride membranes. Membranes
were blocked for 1 h with 5% wt/vol dry milk in Tris-buffered
saline containing 0.1% Tween-20, and incubated with primary
antibodies (Invitrogen, Carlsbad, CA) in blocking buffer overnight
at 4uC, followed by incubation with HRP-conjugated secondary
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Proteins
were visualized using ECL detection system (GE Healthcare
Biosciences, Pittsburgh, PA).
Statistical Analysis
Statistical analyses were performed using GraphPad Prism
Version 5 (GraphPad Software, San Diego, CA). Differences were
evaluated by one-way ANOVA Kruskal-Wallis test with Dunns
posthoc test and a p value of ,0.05 was considered to be
significant; p value of ,0.01 was indicated as **.
Discussion
In the present study, we addressed the potential mechanism of
action of the probiotic mixture, VSL#3, for its ability to ‘‘boost’’
innate mucosal immune responses by inducing TNF production,
particularly during early phases of gut inflammation, in the SAMP
mouse model of CD-like ileitis [19]. Specifically, we showed that
VSL#3-CM directly stimulates TNF, as well as other innate-type
cytokines, when exogenously applied to ex vivo cultured pre-
inflamed ileal tissues from SAMP mice. These effects were
associated with decreased paracellular permeability and modula-
tion of the epithelial TJ proteins, claudin-2 and occludin, which
are inherently dysregulated in SAMP mice [7]. Interestingly, the
effects of VSL#3-CM were reproduced by stimulation with
exogenously applied recombinant TNF, and abrogated by
blockade with a neutralizing antibody against murine TNF,
confirming a central and direct role of TNF in this process. These
finding are consistent with our previous study showing that the
global effect of VSL#3-induced TNF results in the downstream
prevention of ileitis in young, uninflamed SAMP mice and
improved in vivo barrier function, whereas SAMP with established
disease did not benefit therapeutically from VSL#3 treatment
[19].
The results of our studies show that VSL#3-CM stimulates
TNF production and generates permeability changes in SAMP
and C57BL/6, but not in AKR ilea, suggesting that AKR mice
inherently do not respond to VSL#3. Since SAMP mice are on
a mixed background [12] and contain genes from both C57BL/6
and AKR strains, we speculate that the response to VSL#3 and
TNF in SAMP mice is likely dependent on the contribution of
C57BL/6 genes. Our laboratory is currently investigating this
hypothesis using SAMP consomic mice with specific C57BL/6
chromosomal replacement. The protective effects of TNF in this
model were somewhat surprising considering the established
proinflammatory role of TNF in the pathogenesis of chronic
intestinal inflammation and IBD. However, increasing evidence
suggests that TNF possesses ‘‘paradoxical’’ effects that are
dependent on the phase of disease progression and the presence
of TNFR-bearing effector cells. TNF is a classic proinflammatory
cytokine that is well known to be critically involved in the
pathogenesis of CD, as evidenced by the beneficial effects
following treatment with anti-TNF antibodies (e.g., infliximab)
[34]. However, recent studies have highlighted the anti-inflam-
matory properties of TNF for various cell types [32], particularly
in the gut, and its role in protecting and maintaining the integrity
of the intestinal epithelium [35]. In the present study, epithelial
permeability was restored in ileal tissues from young, pre-inflamed
SAMP mice following exposure to VSL#3-CM, and reversed
upon treatment with a neutralizing antibody against TNF.
Furthermore, we previously demonstrated that VSL#3 not only
promotes epithelial TNF production, but also stimulates NF-kB
activation in IEC [19]. As such, VSL#3-dependent NF-kB
regulation in IEC may play a key role in epithelial barrier
function and protection. In support of this concept, deletion of the
NF-kB activator, IkB kinase b (IKKb), specifically in IEC
(IKKbIEC2/2), does not prevent dextran sodium sulfate (DSS)-
induced colitis [36], and mice selectively defective in IEC for the
main IKK subunit, IKKc (IKKcIEC2/2), spontaneously develop
colitis [37].
The protective effects of TNF during acute phases of gut
inflammation are further supported by a study reporting that TNF
deletion in mice leads to increased severity and exacerbation of
disease in acute DSS-induced colitis [38]. Moreover, TNFRI-
mediated activation of innate immunity has been shown to play an
important role in preventing intestinal damage-associated mortal-
ity [39] and is protective in the trinitrobenzene sulfonic acid mouse
model of colitis [40,41]. More recently, TNF was shown to
suppress acute intestinal inflammation though a mechanism that
involves local glucocorticoid synthesis within the gut mucosa [42].
Since DSS-induced colitis is partially mediated by IEC apoptosis,
an alternative hypothesis is that TNF inhibits IEC apoptosis, thus
improving overall intestinal barrier function. Further studies are
warranted to establish the validity of this hypothesis. Therefore,
altogether these results suggest that TNF may possess protective,
homeostatic activities, particularly in the GI tract, which may be
specific for early, acute phases of inflammation. During this time,
the first, initial response of the mucosal environment may be to
enhance innate immunity against luminal antigens through the
production of innate-type cytokines in an attempt to return the gut
to a state of mucosal homeostasis. Defects or dysregulation in the
host’s ability to mount appropriate, early innate immune responses
may therefore result in the initiation and perpetuation of chronic
intestinal inflammation. In addition, the possibility exists that
during chronic, established ileitis, the effects of probiotics, and
induced epithelial TNF, are not effective due to either the presence
of copious amounts of macrophage-derived TNF, different TNFR-
bearing effector cell populations during later, chronic phases of
intestinal inflammation, or actual downregulation of TNFRs, likely
as a negative feedback mechanism in response to increasing local
levels of TNF.
Abnormalities in SAMP small intestinal barrier function are
accompanied, as previously reported [8], by alterations in TJ
proteins with an overexpression of claudin-2 and decreased
expression of occludin. In this context, several studies have shown
that increased claudin-2 and decreased occludin expression in
epithelial TJs result in barrier dysfunction [13–16]. For example,
overexpression of claudin-2 in MDCK I cells leads to increased
epithelial paracellular permeability due to aberrant claudin-2/
claudin-2 pairing on adjacent cells compared to pairings with
other claudin (1–4) proteins [15]. Conversely, overexpression of
occludin in MDCK cells results in an increased number and width
of TJ connections and a decrease in epithelial paracellular
permeability, indicative of a tighter barrier [14]. These aforemen-
tioned trends in claudin-2 and occludin expression have also been
reported in patients with both CD and UC [17,18,43]. Neverthe-
less, in claudin-2 and occludin deficient mice, structure and
function of TJ proteins in the small intestine are indistinguishable
from those of wild type control mice [44]. However, these results
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deserve careful consideration since compensatory mechanisms
may exist in genetically-manipulated mice that underestimate the
physiological relevance of these molecules. One of the most
interesting findings of our study is the ability of VSL#3-CM and
TNF to decrease ex vivo ileal paracellular permeability and to
regulate the expression of epithelial TJ proteins. Specifically,
upregulation of occludin in the insoluble (membrane) fraction of
IEC isolated from SAMP treated with VSL#3 suggests that
occludin may function as the prominent TJ protein regulating
barrier function in response to probiotic treatment. In fact, one of
the beneficial roles of probiotics is to promote intestinal barrier
integrity by influencing the structure of TJ proteins [45]. In
addition, in vivo studies have demonstrated the global protective
effects of probiotics on the gut epithelium in different animal
models of intestinal inflammation [46–48]. In particular, VSL#3
has been shown to improve intestinal barrier function in DSS-
induced colitis by preventing the reduction and redistribution of
TJ proteins, specifically augmenting the expression of ZO-1, and
by inhibiting increases in the apoptotic ratio [45]. Thus, the
protective effects of TNF-induced VSL#3 treatment in SAMP
mice could be partially attributed to inhibition of IEC apoptosis.
Further studies are warranted in order to fully address this
mechanism. Moreover, in vitro treatment of epithelial cells with
probiotics, or metabolites secreted by probiotics, leads to an
increase in ZO-1 and occludin expression, while decreasing
claudin-2 [46]; this study also demonstrated the ability of
probiotics, or probiotic by-products, to either directly or indirectly
modulate epithelial paracellular permeability and control ion
selectivity of TJs [46].
Epithelial TJ proteins represent the principal determinants of
intestinal paracellular permeability and, although mechanism(s)
leading to changes in epithelial TJ protein expression have been
extensively investigated, it remains to be proven what specific
conditions lead to alterations in particular TJ proteins and overall
TJ disruption. In fact, much work has focused on cytokine-
dependent regulation of the TJ complex. In this context, a direct
role of TNF has been implicated in causing loss of barrier function
in cultured intestinal epithelial cell monolayers [49,50]. In
addition, treatment with infliximab (anti-TNF) has been reported
to restore barrier function in CD, and some UC, patients [51–53].
However, conflicting studies exist regarding the interpretation of
the effects of TNF that may reflect differences in the specific
epithelial cell line used or variations in the dose and length of the
treatment with TNF [54]. For example, in the intestinal epithelial
cell line, Caco-2, TNF stimulation results in a delayed effect on
permeability by increasing small molecule flux within 24 hrs, but
reduction in TEER is not observed until 48 hrs post treatment
[55]. IFNc also represents a proinflammatory cytokine found at
elevated levels in the intestinal mucosa of IBD patients, that in
addition to its immunomodulatory role during chronic inflamma-
tion, acts directly to regulate epithelial and endothelial barrier
function [56–58]. Interestingly, a recent report shows that IFNc
exacerbates intestinal inflammation by distinct temporal regulation
of converging b-catenin signaling pathways, and this effect is
potentiated by TNF, which synergistically cooperates to promote
cell proliferation and thereby, potential healing. Conversely
however, extended exposure to these cytokines appears to inhibit
epithelial cell proliferation and apoptosis [59]. As such, temporal
(phase and length) and quantitative differences in the expression
patterns of particular proinflammatory mediators, as well as their
specific receptors, may influence mechanistic diversity in TJ
protein expression and function, and likely reflects changes in
overall barrier integrity during acute versus chronic phases of gut
inflammation. Our results demonstrate a central role of TNF in
ameliorating paracellular permeability during early phases of ileitis
in a spontaneous model of CD-like ileitis that closely resembles the
human condition.
Our studies have significant and translational implications since
it is well known that up to 50% of CD patients do not respond to
anti-TNF treatment modalities [60]. Interestingly, whether anti-
TNF therapy exacerbates disease activity in patients classified as
‘‘non-responders’’ is not routinely evaluated in clinical practice.
Based on the results of our studies, we speculate that individuals
who fall into this ‘‘non-responder’’ patient population may be in
a disease state/phase that depends on the anti-inflammatory
properties of TNF, rather than its recognized proinflammatory
activity. As such, it would interesting to evaluate whether
‘‘boosting’’ the innate immune system by using probiotic therapy
would produce beneficial effects in this patient population.
Taken together, our study further support the hypothesis that
CD may be initiated by a deficit in intestinal innate immunity,
rather than an overly aggressive adaptive immune response to
luminal antigens in which innate-type cytokines, such as TNF,
play a critical role [61]. This working hypothesis, and the role the
probiotic formulation, VSL#3, may play in improving epithelial
barrier function and subsequent gut inflammation, in ileitis-prone
SAMP mice is summarized in Fig. S1. In this context, ‘‘boosting’’
the intestinal innate immune system with immunostimulatory
agents, such as probiotics, and before the onset of disease, may
represent a novel therapeutic modality to prevent or induce a state
of permanent remission in patients with CD.
Supporting Information
Figure S1 Working hypothesis of TNF-dependent pro-
biotic modulation of epithelial barrier function during
the early phases inflammation. One of the earliest features
characteristic of ileitis-prone SAMP mice are epithelial alterations,
including global changes in epithelial architecture, expansion of
villi, as well as Paneth and goblet cell hyperplasia. Interestingly, an
inherent increase in small intestinal epithelial paracellular
permeability is also present in young SAMP, prior to the onset
of inflammation (left). Upon treatment of SAMP mice with VSL#3
during the early phases of inflammation, ‘‘boosting’’ of innate-type
responses occurs, which include production of IEC-derived TNF
and other early innate cytokines, including IL-1 and IL-6, as well
as the anti-inflammatory cytokine, IL-10. In addition, VSL#3-
induced TNF decreases ileal epithelial paracellular permeability
by modulating the TJ proteins, claudin-2 (decrease) and occludin
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